Crescent Biopharma reports news about its clinical-stage oncology pipeline, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugate programs such as CR-002 and CR-003. Company updates commonly cover clinical trial activity in solid tumors, pipeline combinations, collaboration activity, financial results, and business highlights.
Recurring corporate announcements also include investor conference presentations and equity inducement awards under the company’s employment inducement incentive plan. These updates reflect Crescent’s status as a Nasdaq-listed biotechnology issuer focused on cancer therapeutics.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced the grant of non-qualified stock options for 1,647,600 shares to Harout Semerjian, the new President and CEO, on August 3, 2021. The options were part of his inducement to accept the position, with a base exercise price of $2.03 per share. Vesting includes standard timelines and is contingent upon FDA approval of the candidate uproleselan for relapsed/refractory acute myeloid leukemia. GlycoMimetics is focused on developing therapies leveraging glycobiology for serious diseases.
GlycoMimetics, Inc. (Nasdaq: GLYC) reported a cash position of $118.9 million as of June 30, 2021. The company is advancing six clinical trials for its lead candidate, uproleselan, including three registration trials, with anticipated data flow beginning in 2022. Enrollment is expected to conclude by year-end 2021 in pivotal studies addressing AML. Additionally, the announcement of a new CEO, Harout Semerjian, aims to reinforce the company's strategic direction and pipeline development as it progresses towards commercialization.
GlycoMimetics, Inc. (Nasdaq: GLYC) appointed Harout Semerjian as CEO effective August 6, 2021, succeeding founding CEO Rachel King. Semerjian, with extensive oncology commercialization experience, will guide the firm through registrational trials for its lead candidate, uproleselan, in AML. King, who has led the company for 18 years, will remain as a board member and advisor. Semerjian’s experience includes leadership roles at Novartis and Ipsen, and he emphasizes the potential of uproleselan, which holds Breakthrough Therapy Designation from the FDA and Chinese regulators.
GlycoMimetics, Inc. (Nasdaq: GLYC) will hold a conference call on August 5, 2021, at 8:30 a.m. ET to discuss its second-quarter financial results. Domestic participants can dial (844) 413-7154, while international callers should use (216) 562-0466, entering participant code 9977599. A replay will be available on the company's website and via dial-in for 24 hours post-call. GlycoMimetics, based in Rockville, MD, focuses on glycobiology therapies targeting cancers like acute myeloid leukemia (AML) and has received Breakthrough Therapy Designation for its lead drug, uproleselan.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced the initiation of a Phase 1b/2 clinical trial for uproleselan, aimed at treating patients with treated secondary acute myeloid leukemia (ts-AML). The trial, led by Dr. Tapan Kadia at The University of Texas MD Anderson Cancer Center, focuses on the drug's safety, tolerability, and efficacy in a high-risk patient cohort. Uproleselan, a breakthrough therapy candidate, targets E-selectin to overcome treatment resistance in these patients. The study will enroll around 25 participants, assessing various efficacy endpoints.
GlycoMimetics, Inc. (Nasdaq: GLYC) has commenced a clinical study at UC Davis Comprehensive Cancer Center to evaluate uproleselan combined with venetoclax and azacitidine for older patients with treatment-naïve acute myeloid leukemia (AML). The trial aims to address unmet needs in AML treatments, particularly in patients exhibiting drug resistance. Early results from preclinical studies indicate that uproleselan may improve responses in patients resistant to current therapies. A recommended Phase 2 dose will be established, with preliminary results expected in 2022.
GlycoMimetics, Inc. (Nasdaq: GLYC) announces that CEO Rachel King will present a company overview at the Jefferies 2021 Virtual Healthcare Conference on June 3, 2021, from 2:30 to 2:55 p.m. The company focuses on developing glycobiology-based therapies for acute myeloid leukemia (AML) and breast cancer. Its leading drug candidate, uproleselan, has received Breakthrough Therapy Designation in the U.S. and China and is being evaluated in a Phase 3 trial for relapsed/refractory AML. More details are available on their website.
GlycoMimetics, Inc. (Nasdaq: GLYC) has initiated an investigator-sponsored trial at Washington University School of Medicine to evaluate uproleselan's effectiveness in mitigating gastrointestinal toxicities associated with high-dose melphalan in patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. The Phase 2 study, led by Dr. Keith Stockerl-Goldstein, focuses on reducing diarrhea severity and assessing oral mucositis as secondary endpoints. Findings are expected by mid-2022, with uproleselan's prior Phase 2 results indicating potential benefits.
GlycoMimetics, Inc. (Nasdaq: GLYC) reported financial results for Q1 2021, highlighting cash and cash equivalents of $132.5 million. The company is optimistic about its lead program, uproleselan, which received Breakthrough Therapy Designation in China and has ongoing Phase 3 trials in the U.S. and NCI. Research and development expenses fell to $11.2 million, while general and administrative expenses decreased to $4.2 million. The promotion of Eric Feldman to Chief Medical Officer underscores leadership strength.
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call on May 3, 2021, at 8:30 a.m. ET to discuss its first quarter financial results. Domestic participants can dial (844) 413-7154, while international participants should call (216) 562-0466, using participant code 9891637. A replay of the webcast will be available on the company’s website for 30 days post-call. GlycoMimetics focuses on hematology-oncology, with drug candidates including uproleselan and rivipansel, designed for unmet medical needs in these fields.